Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer

Journal of Surgical Oncology

Volumn 97, Issue 1, 2008, Pages 30-34

  Sasa, Mitsunori ^a   Bando, Yoshimi ^b   Takahashi, Masako ^a   Hirose, Toshiyuki ^c   Nagao, Taeko ^b  

^a Tokushima Breast Care Clinic   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c National Hospital Organization   (Japan)

Author keywords

Basal phenotype; Breast cancer; Nodal status; Non basal phenotype; Triple negative

Indexed keywords

CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER SCREENING; CONFERENCE PAPER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-14; KERATIN-17; KERATIN-5; KERATIN-6; LYMPHATIC METASTASIS; MIDDLE AGED; PHENOTYPE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 38149003050     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20906     Document Type: Conference Paper

References (23)

1. Yasunaga H, Ide H, Imamura T, et al.: Women's anxieties caused by false positives in mammography screening: A contingent valuation survey. Breast Cancer Res Treat 2007;101:59-64.
2. Cleator S, Heller W, Coombers RC: Triple-negative breast cancer: Therapeutic options. Lancet Oncol 2007;8:235-244.
3. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinincal implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
4. Perou CM, Sorlie T, van Eisen MB, et al.: Molecular portraits of human breast tumors. Nature 2000;406:747-752.
5. Van't Veer LJ, Dai H, van de Vijver MJ: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
6. Rouzier R, Perou C, Symmans WF, et al.: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685.
7. Rakha EA, EI-Sayed ME, Green AR, et al.: Prognostic markers in triple negative breast cancer. Cancer 2006;109:25-32.
8. Rakha EA, Putti TC, EI-Rehim DMA, et al.: Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506.
9. Jimenez RE, Wallis T, Visscher DW: Centrally necrotizing carcinomas of the breast: A distinct histologic subtype with aggressive clinical behavior. Am J Surg Pathol 2001;25:331-337.
10. Nielsen TO, Hsu FD, Jensen K, et al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
11. Kim M-J, Ro JY, Ahn SH, et al.: Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu- overexpressing phenotypes. Hum Pathol 2006;37:1217-1226.
12. Haffty BG, Yang Q, Reiss M, et al.: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Onol 2006;24:5652-5657.
13. Siziopkou KP, Cobleigh M: The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007;16:104-107.
14. Falo C, Monero A, Varela M, et al.: HER-2/neu status and response to CMF: Retrospective study in a series of operative breast cancer treated with primary CMF chemotherapy. J Cancer Res Clin Oncol 2007;133:423-429.
15. Yuli C, Shao N, Rao R, et al.: BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers. Oncogene 2007;26:1-7.
16. Livasy CA, Karaca G, Nanda R, et al.: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-271.
17. Carey LA, Perou CM, Livasy CA, et al.: Race, breast cancer subtypes, and survival in Carolina Breast Cancer Study. JAMA 2006;295:2492-2502.
18. Giorgi UD, Rosti G, Frassineti L, et al.: High dose chemotherapy for triple negative breast cancer. Ann Oncol 2007;18:202-203.
19. Rodenhuis S, Bontenbal M, van Hoesel QGCM, et al.: Efficacy of high-dose alkylating chemotherapy in Her2/neu-negative breast cancer. Ann Oncol 2006;17:588-596.
20. Altundag K, Harputluoglu H, Aksoy S, et al.: Potential chemotherapy options in the triple negative subtype of breast cancer. J Clin Oncol 2007;25:1294-1295.
21. Dabbs DJ, Chivukula M, Carter G, et al.: Basal phenotype of ductal carcinoma in situ: Recognition and immunohistologic profile. Mod Pathol 2006;19:1506-1511.
22. Finn RS, Dering J, Ginther C, et al.: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007: Feb 1; [Epub ahead of print].
23. Huang FH, Reeves K, Han X, et al.: Identification of candidate molecular markers predicting sensitivity in solid tumors to Dasatinib: Rationale for patient selection. Cancer Res 2007;67:2226-2238.